Adaptimmune Therapeutics (NASDAQ:ADAP) Now Covered by StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP) in a research report issued to clients and investors on Saturday. The firm set a “buy” rating on the biotechnology company’s stock.

A number of other research analysts also recently issued reports on the stock. Guggenheim reduced their price target on shares of Adaptimmune Therapeutics from $3.00 to $1.75 and set a “buy” rating on the stock in a research report on Wednesday. Wells Fargo & Company cut their target price on shares of Adaptimmune Therapeutics from $2.00 to $1.50 and set an “equal weight” rating on the stock in a report on Friday, March 21st. Finally, Scotiabank lowered their target price on Adaptimmune Therapeutics from $3.15 to $1.40 and set a “sector outperform” rating for the company in a report on Friday, March 21st. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $1.93.

Adaptimmune Therapeutics Trading Down 6.4 %

NASDAQ:ADAP opened at $0.21 on Friday. The company has a market cap of $52.71 million, a PE ratio of -0.94 and a beta of 2.52. The business’s 50 day moving average is $0.51 and its two-hundred day moving average is $0.67. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.62. Adaptimmune Therapeutics has a 52 week low of $0.20 and a 52 week high of $1.55.

Adaptimmune Therapeutics (NASDAQ:ADAP) last posted its quarterly earnings results on Monday, March 24th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.09). The firm had revenue of $3.22 million for the quarter, compared to analyst estimates of $16.56 million. Adaptimmune Therapeutics had a negative net margin of 25.43% and a negative return on equity of 74.15%. On average, analysts predict that Adaptimmune Therapeutics will post -0.14 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ADAP. Invesco Ltd. raised its holdings in shares of Adaptimmune Therapeutics by 82.0% during the fourth quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company’s stock valued at $34,000 after buying an additional 28,526 shares during the last quarter. Two Sigma Advisers LP raised its stake in Adaptimmune Therapeutics by 492.0% during the 4th quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company’s stock valued at $38,000 after acquiring an additional 58,787 shares in the last quarter. Two Sigma Investments LP raised its stake in Adaptimmune Therapeutics by 33.5% during the 4th quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 19,146 shares in the last quarter. Virtu Financial LLC boosted its position in Adaptimmune Therapeutics by 27.5% during the 3rd quarter. Virtu Financial LLC now owns 101,008 shares of the biotechnology company’s stock worth $96,000 after acquiring an additional 21,769 shares during the period. Finally, Jane Street Group LLC grew its stake in shares of Adaptimmune Therapeutics by 130.4% in the third quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company’s stock worth $166,000 after purchasing an additional 98,581 shares in the last quarter. 31.37% of the stock is owned by institutional investors and hedge funds.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.